SynthesisBMC cardiovascular disorders2026
Exploring the benefits and safety of combining nebivolol and valsartan for managing hypertension: a systematic review.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is considered the world's leading risk factor for mortality. Many individuals with hypertension need to take multiple blood pressure (BP)-lowering medications. Combining Nebivolol, a third-generation beta-blocker, and Valsartan, an angiotensin receptor blocker (ARB), presents a promising therapeutic approach for BP management. Although several clinical studies have evaluated this combination, evidence regarding its overall efficacy and safety remains fragmented. This study aims to evaluate the efficacy and safety of this combination therapy.
methodThe systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic literature search was conducted across PubMed, Scopus, and the Cochrane Library from inception until February 2025. The studies that met the requirements to assess the safety and effectiveness of a combination therapy of nebivolol and valsartan for the treatment of hypertension included open-label studies, crossover trials, and randomized controlled trials (RCTs). Databases searched included PubMed, Scopus, and Cochrane Library. The main topics of data extraction were the changes in systolic and diastolic blood pressure (SBP/DBP), cardiovascular events, treatment adherence, and quality-of-life measures. The risk of bias was assessed using ROB 2.0 and ROBINS-I frameworks.
resultsOut of 99 initially screened studies, six met the inclusion criteria, including two randomized controlled trials (one of which generated two prespecified sub-analyses), one open-label single-arm study, and one crossover trial. The results showed that combining Nebivolol and valsartan decreased SBP and DBP. The highest dose (20/320 mg) achieved a mean SBP reduction of -15.4 mmHg and a DBP reduction of -10.0 mmHg over 8 weeks. Long-term Studies of a 52-week duration showed sustained blood pressure control, with an average drop in SBP of -25.5 mmHg and a drop in DBP of -19.0 mmHg. Additionally, the combination improved heart rate variability and reduced renin-angiotensin-aldosterone system activity. Clinical trials have reported that Nebivolol has a favorable safety profile, with mild and transient symptoms, including fatigue, headache, dyspnea, insomnia, dizziness, and paresthesia, making it a patient-preferred option.
conclusionThis systematic review provides evidence for the safety and efficacy of the nebivolol-valsartan combination as an antihypertensive regimen. The combination is also beneficial in terms of hemodynamic parameters and overall cardiac load. Nevertheless, large-scale, long-term trials are needed to confirm these results and to define who can benefit most from this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.